Heart attack survivors may benefit from diabetes drug, new study suggests
NCT ID NCT07351643
First seen Jan 21, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study tests whether dapagliflozin, a drug typically used for diabetes, can reduce inflammation in the heart arteries of people who have had a heart attack but do not have diabetes or heart failure. About 110 participants will receive either the drug plus standard care or standard care alone for 6 months. Inflammation is measured using a special CT scan of the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACS (ACUTE CORONARY SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.